

Characteristics	Risk		Total
	LR	IR/HR	
Target dose(g/m ²)	3	5	-
Patients	135(45.9%)	159(54.1%)	294
Age (years; range)	4.1(1.2-9.8)	5.9(0.4-14)	4.8(0.4-14)
Sex			
Female	59(43.7%)	60(37.7%)	119(40.5%)
Male	76(56.3%)	99(62.3%)	175(59.5%)
Immunophenotype			
B-ALL	135(100%)	133(83.6%)	268(91.2%)
T-ALL	0	26(16.4%)	26(8.8%)
Cycles(N)	538	634	1172
Actual MTX dose (g/m ²)	3.00(2.4-3)	4(3.5-5)	-
MTX infusion rate ^b	1.0(0.8-1.0)	0.8(0.7-1.0)	-
Leucovorin dose(mg/m ²)	75(75-120)	75(75-255)	-
C _{44h} (μ mol/L) ^c	0.47(0.34-0.74)	0.67(0.44-1.60)	
<0.5	295(54.8%)	209(33%)	504(43%)
0.5-1	146(27.1%)	215(33.9%)	361(30.8%)
>1	97(18%)	210(33.1%)	307(26.2%)
C _{68h} (μ mol/L) ^c	0.14(0.1-0.22)	0.2(0.11-0.39)	
<0.2	391(72.7%)	345(54.4%)	736(62.8%)
≥0.2	147(27.3%)	289(45.6%)	436(37.2%)

^a The values are expressed as number (%) or median (p25-p75);

^b MTX infusion rate =actual MTX dose(m2)/target dose (m2);

^c C_{44h}: MTX concentration at 44h; C_{68h}: MTX concentration at 68h

TABLE 1 Baseline patient demographics, treatment data and laboratory values based on risk group ^a